First, although we clearly demonstrated that IGF-1 attenuated cardiac fibrosis in an AngII-infusion mouse model, cardiac fibrosis is already present in pathological conditions, such as hypertension or myocardial infarction, when antifibrotic treatment is started in humans. Here, AGT is linked to myocardial infarction.